Almac Strengthens Board with Appointment of New Financial Director
News Apr 10, 2012
The Almac Board has announced the appointment of Kevin Stephens to the executive position of Finance Director, Almac Group, with effect from 1 January 2012.
Kevin will take responsibility for all financial aspects of Almac Group activities globally, leading the financial management teams for all global operations, supporting the planned growth of the business and co-ordinating financial control and reporting throughout the Group.
After graduating from Queen’s University, Belfast, with a degree in Economics, Kevin qualified as a Chartered Accountant with Ernst & Young and then worked for 14 years with Kemira NI as Financial Controller.
Kevin joined the Group in 2001 and following a number of varied financial roles within the organization, he was appointed to the position of Almac UK Group Financial Controller in January 2007.
He was promoted to the role of VP Finance, Almac Group, in July 2009, and subsequently in October 2010 was appointed to the Almac Executive team as Executive VP Finance, Almac Group.
Alan Armstrong, CEO of the Almac Group commented: “We are delighted to appoint Kevin to this important financial position on our Board. Not only does he possess strong financial qualifications and training, he also has very specific knowledge and experience of the workings of the Almac Group having held a string of financial positions within the organization. Indeed, we anticipate that Kevin will play a key strategic role in the continued growth and successful financial management of our Group of companies.”
Concept Life Sciences appoints New Group Programme Manager and US Head of SalesNews
Key leadership appointments support integration of the Group and expansion in the US market.READ MORE
Alzheimer’s Drug Discovery Foundation Announces $1.8M in New FundingNews
The Alzheimer’s Drug Discovery Foundation (ADDF) announces nearly $1.8 million in new funding, which reflects a commitment to advancing drugs in or near human clinical trials. All five funded programs are potential treatments for Alzheimer’s disease and other forms of dementia.READ MORE